Title : Demyelinating diseases: myeloperoxidase as an imaging biomarker and therapeutic target.

Pub. Date : 2012 May

PMID : 22438365






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 EAE was induced in SJL mice by using proteolipid protein (PLP), and mice were treated with either 4-aminobenzoic acid hydrazide (ABAH), 40 mg/kg injected intraperitoneally, an irreversible inhibitor of MPO, or saline as control, and followed up to day 40 after induction. 4-aminobenzhydrazide myeloperoxidase Mus musculus
2 Inhibiting MPO activity with ABAH resulted in decrease in MPO-Gd-positive lesion volume (P = .012), number (P = .009), and enhancement intensity (P = .03) at MR imaging, reflecting lower local MPO activity (P = .03), compared with controls. 4-aminobenzhydrazide myeloperoxidase Mus musculus
3 Inhibiting MPO activity with ABAH resulted in decrease in MPO-Gd-positive lesion volume (P = .012), number (P = .009), and enhancement intensity (P = .03) at MR imaging, reflecting lower local MPO activity (P = .03), compared with controls. 4-aminobenzhydrazide myeloperoxidase Mus musculus
4 Inhibiting MPO activity with ABAH resulted in decrease in MPO-Gd-positive lesion volume (P = .012), number (P = .009), and enhancement intensity (P = .03) at MR imaging, reflecting lower local MPO activity (P = .03), compared with controls. 4-aminobenzhydrazide myeloperoxidase Mus musculus